A gene therapy designed for one child

What the CPS1 case teaches us about personalised medicine.

5 September 20261 min read

Anna Maria Journal · Clinical case · 1 patient

Study / event: 15 May 2025 · Explained in perspective

Conceptual illustration: A gene therapy designed for one child — Conceptual illustration; not experimental data or microscopy.

Key takeaway

An early result can open a research direction without yet proving long-term safety.

What was studied

In 2025, a team developed gene editing tailored to the variant of an infant with severe CPS1 enzyme deficiency. The treatment was delivered using lipid nanoparticles. The paper reported two infusions and seven weeks of follow-up after the first.

NEJM [1]

What was found

During that period, the child tolerated more dietary protein and received half the starting dose of a medicine that helps remove nitrogen. No serious adverse events were reported.

NEJM [1]

What it does not prove

This was one patient, without a comparison group and with short initial follow-up. It does not establish a permanent cure or applicability to other diseases. Funding came from the NIH and other sources.

NEJM [1]

Why it matters

The significance lies in adapting treatment to a specific genetic change. The next question is whether benefit and safety persist, and whether the approach can be repeated.

NEJM [1]